entertainment -WSS

entertainment

author：knowledge 2025-09-02 08:18:46 - browse：7

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

WSS

Sanders wants to replace patents with prizes for drug inventions

The best solution to the drug shortages problem

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Scientists grapple with ethics of stem cell research

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

What does generative AI mean for health care? We asked experts

Scientists grapple with ethics of stem cell research

Supreme Court strikes down use of affirmative action

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

At least 13 dead in Texas as scorching temps continue

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

What does generative AI mean for health care? We asked experts

The stock market has soared this year, but will it last? Experts weigh in

Medicare details structure of new drug price negotiation program

Telehealth startups are trying to fill the menopause care vacuum

hotspot

Friends ask where James Watson's attitudes about race came from

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Wegovy’s successful heart trial raises vital question about weight loss

In rare move, senator releases unverified FBI source report alleging Biden bribe

Delta passengers in Vegas fall sick while waiting on flight in triple

How to use technology to prevent future drug shortages

hotspot

knowledge

hotspot

hotspot